Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| LianBioLIAN · Entity 9881 | SVP, China General Manager | March 29, 2023 | March 31, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
LianBio
Report date March 29, 2023 · Filed March 31, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 291,354 |
Reported balance
After 2023-03-29 transaction · row 1
1 source rowRow 1 · 2023-03-29 · Grant · Acquired 224,005 · Balance 291,354 F1: Represents restricted share units granted to the Reporting Person under the LianBio 2021 Equity Incentive Plan. Each restricted share unit represents the contingent right to receive one share of the Issuer's Ordinary Shares. 25% of the restricted share units shall vest on March 29, 2024; the remainder shall vest in 25% annual installments such that the restricted share units are fully vested on March 29, 2027, subject to the Reporting Person providing continuous service to the Issuer on each such date. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents restricted share units granted to the Reporting Person under the LianBio 2021 Equity Incentive Plan. Each restricted share unit represents the contingent right to receive one share of the Issuer's Ordinary Shares. 25% of the restricted share units shall vest on March 29, 2024; the remainder shall vest in 25% annual installments such that the restricted share units are fully vested on March 29, 2027, subject to the Reporting Person providing continuous service to the Issuer on each such date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 29, 2023 Filed Mar 31, 2023 20:20 UTC | LianBio LIAN · Entity 9881 | GrantOrdinary Shares | 224,005 | $0.00 | $0.00 |
DisclosureSEC source: 0001831283-23-000053 · wf-form4_168029404088883.xml · nonDerivative · entry 1 QIAN JIANG · CIK 0001880938 · SVP, China General Manager 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 291,354 F1 · shares: Represents restricted share units granted to the Reporting Person under the LianBio 2021 Equity Incentive Plan. Each restricted share unit represents the contingent right to receive one share of the Issuer's Ordinary Shares. 25% of the restricted share units shall vest on March 29, 2024; the remainder shall vest in 25% annual installments such that the restricted share units are fully vested on March 29, 2027, subject to the Reporting Person providing continuous service to the Issuer on each such date. Read SEC document |
| January 20, 2023 Filed Jan 24, 2023 21:09 UTC | LianBio LIAN · Entity 9881 | GrantStock Option (Right to Buy) · Derivative | 318,995 | $0.00 Strike: $2.66 | $0.00 |
DisclosureSEC source: 0001831283-23-000016 · wf-form4_167459457187041.xml · derivative · entry 1 QIAN JIANG · CIK 0001880938 · SVP, China General Manager 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 318,995 Underlying: Ordinary Shares · 318,995 shares Expires 2033-01-20 F1 · derivative.exercise_date: 25% of the shares underlying the option will vest and become exercisable on January 20, 2024; the remainder shall vest and become exercisable in 36 equal monthly installments such that the option shall be fully vested on January 20, 2027, subject to the Reporting Person providing continuous service to the Issuer on each such date. Read SEC document |
| January 03, 2023 Filed Jan 5, 2023 21:29 UTC | LianBio LIAN · Entity 9881 | SaleOrdinary Shares | 2,239 | $1.65 | $3,701.51 |
DisclosureSEC source: 0001831283-23-000002 · wf-form4_167295415423471.xml · nonDerivative · entry 1 QIAN JIANG · CIK 0001880938 · SVP, China General Manager 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,349 F1 · shares: Sale of shares to cover personal income tax obligations upon vesting of restricted share units as required pursuant to the terms of Mr. Qian's restricted share unit award agreement. Read SEC document |
| December 31, 2021 Filed Jan 3, 2022 21:15 UTC | LianBio LIAN · Entity 9881 | GrantOrdinary Shares | 69,588 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-22-000126 · doc4.xml · nonDerivative · entry 1 QIAN JIANG · CIK 0001880938 · China General Manager 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 69,588 F1 · shares: Represents restricted share units granted to the Reporting Person under the LianBio 2021 Equity Incentive Plan. Each restricted share unit represents the contingent right to receive one share of the Issuer's Ordinary Shares. 25% of the restricted share units shall vest on December 31, 2022; the remainder shall vest in 25% annual installments such that the restricted share units are fully vested on December 31, 2025, subject to the Reporting Person providing continuous service to the Issuer on each such date. Read SEC document |
| October 31, 2021 Filed Nov 1, 2021 23:26 UTC | LianBio LIAN · Entity 9881 | GrantStock Option (Right to Buy) · Derivative | 409,343 | $0.00 Strike: $16.00 | $0.00 |
DisclosureSEC source: 0000899243-21-042220 · doc4.xml · derivative · entry 1 QIAN JIANG · CIK 0001880938 · China General Manager 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 409,343 Underlying: Ordinary Shares · 409,343 shares Expires 2031-10-31 F1 · derivative.exercise_date: 1/4 of the shares underlying the option will vest and become exercisable on October 31, 2022; the remainder shall vest and become exercisable in 36 equal monthly installments such that the option shall be fully vested on October 31, 2025, subject to the Reporting Person providing continuous service to the Issuer on each such date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.